The cyclopentenone 15-deoxy-Δ12,14-prostaglandin J 2 inhibits G1/S transition and retinoblastoma protein phosphorylation in immortalized lymphocytes from Alzheimer's disease patients

Experimental Neurology

Volumn 195, Issue 2, 2005, Pages 508-517

  Muñoz, Úrsula ^a   De Las Cuevas, Natividad ^a   Bartolomé, Fernando ^a   Hermida, Ofelia G ^a   Bermejo, Félix ^b   Martín Requero, Ángeles ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Alzheimer's disease; Cell cycle; Cyclopentenone; Lymphocytes; p27

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITRO N 4 PYRIDINYLBENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ALITRETINOIN; BENZAMIDE DERIVATIVE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLOPENTENONE; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR BLOCKING AGENT; RETINOBLASTOMA PROTEIN; ROSIGLITAZONE; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; SERUM;

AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; APOPTOSIS; CASE-CONTROL STUDIES; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LEUPEPTINS; LYMPHOCYTES; MALE; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PHOSPHORYLATION; PPAR GAMMA; PROSTAGLANDIN D2; RETINOBLASTOMA PROTEIN; TIME FACTORS;

EID: 24744468579     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2005.06.010     Document Type: Article

References (52)

1. J.B. Almond, and G.M. Cohen The proteasome: a novel target for cancer chemotherapy Leukemia 16 2002 433 444
2. T. Arendt Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr. Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity Prog. Neurobiol. 71 2003 83 248
3. M. Bamberger, and G. Landreth Microglial interaction with β-amyloid implications for the pathogenesis of Alzheimer's disease Microsc. Res. Tech. 54 2001 59 70
4. J. Berger, and D.E. Moller The mechanisms of action of PPARs Annu. Rev. Med. 53 2002 409 435
5. 2, but not troglitazone, modulates IL-1beta effects in human chondrocytes by inhibiting NF-kappaB and AP-1 activation pathways FEBS Lett. 501 2001 24 30
6. R.C. Braun-Dullaeus, M.J. Mann, A. Ziegler, H.E. von der Leyen, and V.J. Dzaum A novel role for the cyclin-dependent kinase inhibitor p27(Kip1) in angiotensin II-stimulated vascular smooth muscle cell hypertrophy J. Clin. Invest. 104 1999 815 823
7. J.C. Breitner The role of antiinflammatoty drugs in the prevention and treatment of Alzheimer's disease Annu. Rev. Med. 47 1996 401 411
8. 2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit J. Biol. Chem. 276 2001 35530 35536
9. S.P. Chellappan, S. Hiebert, M. Mudryj, J.M. Horowitz, and J.R. Nevins The E2F transcription factor is a cellular target for the RB protein Cell 65 1991 1053 1061
10. kip1 for restriction point control of the fibroblast cell cycle Science 272 1996 877 880
11. kip1 involved in the enhanced proliferation of lymphoblasts from patients with Alzheimer dementia Neurobiol. Dis. 13 2003 254 263
12. N. Cuevas, U. Muñoz, O.G. Hermida, and A. Martín-Requero Altered transcriptional regulators in response to serum in immortalized lymphocytes from Alzheimer's disease patients Neurobiol. Aging 26 2005 615 624
13. Kip1 degradation independently of CDK2/cyclin E in NIH 3T3 cells J. Biol. Chem. 276 2001 34958 34965
14. W. Erl, C. Weber, A. Zennecke, J. Neuzil, C.A. Vosseler, H.J. Kim, and P.C. Weber Cyclopentenone prostaglandins induce endothelial cell apoptosis independent of the peroxisome proliferator-activated receptor-gamma Eur. J. Immunol. 34 2004 241 250
15. M.L. Fero, M. Rivkin, M. Tasch, P. Porter, C.E. Carow, E. Firpo, K. Polyak, L.H. Tsai, V. Broudy, R.M. Perlmutter, K. Kaushansky, and J.M. Roberts A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice Cell 85 1996 733 744
16. D.W. Gilroy, P.R. Colville-Nash, D. Willis, J. Chivers, M.J. Paul-Clark, and D.A. Willoughby Inducible cyclooxygenase may have anti-inflammatory properties Nat. Med. 5 1999 698 701
17. S.W. Han, M.E. Greene, J. Pitts, R.K. Wada, and N. Sidell Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARgamma) in human neuroblastoma cells Clin. Cancer Res. 7 2001 98 104
18. 2 induces IL-8 production in human T cells by a mitogen-activated protein kinase pathway J. Immunol. 168 2002 1372 1379
19. M. Hatakeyama, and R.A. Weinberg The role of RB in cell cycle control Prog. Cell Cycle Res. 1 1995 9 19
20. K. Helin Regulation of cell proliferation by the E2F transcription factors Curr. Opin. Genet. Dev. 8 1998 28 35
21. L. Ho, D. Purohit, V. Haroutunian, J.D. Luterman, F. Willis, J. Naslund, J.D. Buxbaum, R.C. Mohs, P.S. Aisen, and G.M. Pasinetti Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease Arch. Neurol. 58 2001 487 492
22. W. Hu, C.J. Bellone, and J.J. Baldassare RhoA stimulates p27(Kip) degradation through its regulation of cyclin E/CDK2 activity J. Biol. Chem. 274 1999 3396 3401
23. D. Ibarreta, E. Urcelay, R. Parrilla, and M.S. Ayuso Distinct pH homeostatic features in lymphoblasts from Alzheimer's disease patients Ann. Neurol. 44 1998 216 222
24. B.A. int′Veld, A. Ruitenber, A. Hofman, J. Launer, C.M. Van Duijn, T. Stijnen, M.M. Breteler, and B.H. Stricker Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease N. Engl. J. Med. 345 2001 1515 1521
25. N. Janabi Selective inhibition of cyclooxygenase-2 expression by 15-deoxy-Delta(12,14)(12,14)-prostaglandin J(2) in activated human astrocytes, but not in human brain macrophages J. Immunol. 168 2002 4747 4755
26. C. Jiang, A.T. Ting, and B. Seed PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines Nature 391 1998 82 86
27. S. Kersten, B. Desvergne, and W. Wahli Roles of PPARs in health and disease Nature 405 2000 421 424
28. Y. Kitamura, S. Shimohama, H. Koike, J. Kakimura, Y. Matsuoka, Y. Nomura, P.J. Gebicke-Haerter, and T. Taniguchi Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains Biochim. Biophys. Res. Commun. 254 1999 582 586
29. S.A. Kliewer, K. Umesono, D.J. Noonan, R.A. Heyman, and R.M. Evans Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors Nature 358 1992 771 774
30. P. Koistinen Human peripheral blood and bone marrow cell separation using density gradient centrifugation on Lymphoprep and Percoll in haematological diseases Scan. J. Clin. Lab. Invest. 47 1987 709 714
31. A. Krishan Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining J. Cell Biol. 66 1975 188 193
32. G. Lee, F. Elwood, J. McNally, J. Weiszmann, M. Lindstrom, K. Amaral, M. Nakamura, S. Miao, P. Cao, R.M. Learned, J.L. Chen, and Y. Li T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities J. Biol. Chem. 277 2002 19649 19657
33. L.M. Leesnitzer, D.J. Parks, R.K. Bledsoe, J.E. Cobb, J.L. Collins, T.G. Consler, R.G. Davis, E.A. Hull-Ryde, J.M. Lenhard, L. Patel, K.D. Plunket, J.L. Senk, J.B. Stimmel, C. Therapontos, T.M. Willson, and S.G. Blanchard Functional consequences of cysteine modifications in the ligand binding sites of peroxisome proliferators activated receptors by GW9662 Biochemistry 41 2002 6640 6650
34. J.M. Lehmann, J.M. Lenhard, B.B. Oliver, G.M. Ringold, and S.A. Kliewer Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs J. Biol. Chem. 272 1997 3406 3411
35. 2 and the thiazolidinedione ciglitazone through peroxisome proliferator activator receptor-independent mechanisms involving reactive oxygenated species J. Biol. Chem. 277 2002 29681 29685
36. S.S. Millard, J.S. Yan, H. Nguyen, M. Pagano, H. Kiyokawa, and A. Koff Enhanced ribosomal association of p27(kip1) mRNA is a mechanism contributing to accumulation during growth arrest J. Biol. Chem. 272 1997 7093 7098
37. N. Mitsiades, C.S. Mitsiades, V. Poulaki, D. Chauhan, P.G. Richardson, T. Hideshima, N. Munshi, S.P. Treon, and K.C. Anderson Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications Blood 99 2002 4079 4086
38. Z. Nagy, M.M. Esiri, and A.D. Smith The cell division cycle and the pathophysiology of Alzheimer's disease Neuroscience 87 1998 731 739
39. Z. Nagy, M. Combrinck, M. Budge, and R. Mcshane Cell cycle kinesis in lymphocytes in the diagnosis of Alzheimer's disease Neurosci. Lett. 317 2002 81 84
40. K. Niwa, E. Araki, S.G. Morham, M.E. Ross, and C. Iadecola Cyclooxygenase-2 contributes to functional hyperemia in whisker-barrel cortex J. Neurosci. 20 2000 763 770
41. M. Pagano, S.W. Tam, A.M. Theodoras, P. Berromero, G. Delsal, V. Chau, P.R. Yew, G.F. Draetta, and M. Rolfe Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 Science 269 1995 682 685
42. A.K. Raina, X. Zhu, C.A. Rottkamp, M. Monteiro, A. Takeda, and M.A. Smith Cyclin' toward dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer disease J. Neurosci. Res. 61 2000 128 133
43. 2, a specific ligand for peroxisome proliferator-activated receptor-gamma, induces neuronal apoptosis NeuroReport 12 2001 839 843
44. M.J. Serou, M.A. DeCoster, and N.G. Bazan Interleukin-1 beta activates expression of cyclooxygenase-2 and inducible nitric oxide synthase in primary hippocampal neuronal culture: platelet-activating factor as a preferential mediator of cyclooxygenase-2 expression J. Neurosci. Res. 58 1999 593 598
45. 2 on proteasome Biochemistry 42 2003 13960 13968
46. R.S. Spangler Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy Semin. Arthritis Reum. 26 1996 435 446
47. W.F. Stewart, C. Kawas, M. Corrada, and E.J. Metler Risk of Alzheimer's disease and duration of NSAID use Neurology 48 1997 626 632
48. + exchanger Neurobiol. Dis. 8 2001 289 298
49. S. Wakino, K. Hayashi, T. Kanda, S. Tatematsu, K. Homma, K. Yoshioka, I. Takamatsu, and T. Saruta Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2 Circ. Res. 95 2004 e45 e55
50. T.M. Willson, and W. Wahli Peroxisome proliferators-activated receptor agonists Curr. Opin. Chem. Biol. 1 1997 235 241
51. W.L. Yang, and H. Frucht Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells Carcinogenesis 22 2001 1379 1383
52. Y. Yang, E.J. Mufson, and K. Herrup Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease J. Neurosci. 23 2003 409 435